Luisa Berenise Gámez-González
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Luisa Berenise Gámez-González.
European Journal of Pediatrics | 2013
Luisa Berenise Gámez-González; Chiharu Murata; Mireya Muñoz-Ramírez; Marco Yamazaki-Nakashimada
Recently, there have been increasing reports of severe forms of Kawasaki disease (KD) associated with shock that have been managed in pediatric intensive care units. It has been suggested that KD is more severe in the Hispanic population. We conducted a study to determine the frequency of Kawasaki disease shock syndrome (KDSS) in our population and compared characteristics between patients with KD without shock and patients with KDSS. Data from 214 patients with KD treated in a tertiary pediatric hospital were collected during a 12-year period. We compared clinical and laboratory features of KD patients without shock and KDSS patients. Of 214 consecutive patients with KD, 11 (5xa0%) met the definition for KDSS. All of these patients received fluid resuscitation, seven (64xa0%) required inotropic treatment, and six (54xa0%), ventilatory support. On admission, seven of these patients (64xa0%) had an incomplete presentation of the disease, whereas in the group of patients without shock, the relative frequency of an incomplete presentation was 29xa0%. Twenty percent (3/11) of patients with KDSS presented giant coronary aneurysms versus none of 203 KD patients without shock (pu2009=u20090.001); myocardial infarction, 27xa0% (3/11), versus 1xa0% (2/203) (pu2009=u20090.001); and intravenous immunoglobulin (IVIG) resistance, 60xa0% (6/11), versus 12xa0% (24/203). Gastrointestinal manifestations in the acute phase occurred in 91xa0% of KDSS patients versus 30xa0% patients without shock (pu2009=u20090.001). Conclusion. Patients with KD presenting in shock seem to have an increase in gastrointestinal manifestations, incomplete presentation, IVIG resistance, and worse cardiac outcomes. Larger, prospective, multicentre studies should be carried out to corroborate these findings.
Human Vaccines & Immunotherapeutics | 2017
Luisa Berenise Gámez-González; Hiromichi Hamada; Beatriz Llamas-Guillén; Miguel Ruiz-Fernández; Marco Antonio Yamazaki-Nakashimada
ABSTRACT Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30–50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently, Yamada et al. reported a severe BCG reaction with tuberculid in 2 Japanese KD patients. We present 2 cases with KD and severe BCG reaction, one from Japan and the other from Mexico and review the policies of administration of BCG in both countries. The BCG vaccine has a worldwide coverage of 88%. Differences in BCG strains and methods of administration may influence BCG reactions in KD. The BCG reaction in the inoculation site may represent the most useful sign in KD.
Pediatrics International | 2018
Luisa Berenise Gámez-González; Isabel Moribe-Quintero; Martin Cisneros-Castolo; Javier Varela-Ortiz; Mireya Muñoz-Ramírez; Martín Garrido-García; Marco Antonio Yamazaki-Nakashimada
Kawasaki disease shock syndrome (KDSS) is an uncommon presentation of Kawasaki disease (KD). KDSS has been associated with more severe markers of inflammation, coronary abnormalities and i.v. immunoglobulin (IVIG) resistance.
Clinical Rheumatology | 2018
Marco Antonio Yamazaki-Nakashimada; Luisa Berenise Gámez-González; Chiharu Murata; Takafumi Honda; Kumi Yasukawa; Hiromichi Hamada
Previous studies have suggested an association of IgG levels (before and after IVIG infusion) with clinical outcomes in Kawasaki disease. A retrospective analysis was performed that included 418 patients with KD admitted to Tokyo Women’s Medical University Yachiyo Medical Center to evaluate pre- and post-IVIG IgG levels and its relation to outcomes. All patients received an initial IVIG infusion and aspirin; IgG levels were measured in 350 patients before IVIG (pre-IVIG IgG levels) and in 373 patients 48xa0h after starting IVIG infusion (post-IVIG IgG levels). Media and standard deviation of the pre- and post-IVIG IgG levels were reported and classified according to age. Also, IgG z-scores were calculated according to normal values of IgG by age. The number of cases and corresponding percentage of non-responders were reported by age and total patients. The association of pre-IVIG, post-IVIG IgG levels and post-IVIG IgG level/pre-IVIG IgG level ratio with no-response was evaluated by simple logistic regression model based on the IgG z-score, and regression coefficient, X2 value, p, and R2 of Nagelkerke were reported. Pre-IVIG and post-IVIG IgG levels presented an association with non-responders with statistical significance. This association was more evident between post-IVIG IgG levels and non-responders. Regarding coronary alterations, it was not possible to perform an adequate statistical analysis due the small number of patients. Pre- and post-IVIG infusion IgG levels could be an important biomarker in KD as well as in other inflammatory conditions. Higher IgG levels could be associated with a more effective immunomodulatory action and associated with better clinical outcomes.
Clinical Pediatrics | 2018
Luisa Berenise Gámez-González; Hiromichi Hamada; Martín Cisneros Castolo; Takafumi Honda; Kumi Yasukawa; Jun-ichi Takanashi
Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Intravenous immunoglobulin (IVIG) may significantly lower the frequency of coronary artery complications. However, some patients do not respond to initial therapy and are at higher risk of developing coronary artery lesion. A retrospective analysis of data from 419 KD patients was performed. The patients were divided into IVIG responders (n = 318) and IVIG nonresponders (n = 101). Multivariate logistic regression analysis revealed neutrophil percentage, albumin, aspartate aminotransferase, heart rate, and body temperature were independent predictors of IVIG resistance. We generated a predictive scoring system by assigning 1 point for the presence of these parameters (neutrophil >80%, albumin <3.4 g/dL, aspartate aminotransferase >100 IU/L, heart rate >146 bpm, and body temperature >38.8°C). This scoring system had a sensitivity of 76.2% and specificity of 64.8%, and a positive predictive value of 40.1% and a negative predictive value of 89.4%. Vital signs may be helpful to detect KD patients with IVIG resistance.
Revista alergia Mexico | 2017
Martínez-Guzmán E; Luisa Berenise Gámez-González; Francisco Rivas-Larrauri; Sorcia-Ramírez G; Marco Antonio Yamazaki-Nakashimada
Revista Alergia México | 2012
Luisa Berenise Gámez-González; Ana Luisa Rodríguez-Lozano; Francisco Rivas-Larrauri; Marco Antonio Yamazaki-Nakashimada
Annals of Paediatric Rheumatology | 2017
Luisa Berenise Gámez-González; Marco Antonio Yamazaki-Nakashimada
Seminars in Arthritis and Rheumatism | 2016
Mónica Rodríguez-González; Luisa Berenise Gámez-González; Martín Garrido-García; Marco Antonio Yamazaki-Nakashimada
Open Forum Infectious Diseases | 2016
Rolando Ulloa-Gutierrez; Luis M. Garrido-García; Dora Estripeaut; Francisco Rodríguez; Patricia Saltigeral-Simental; Olguita Del Águila; Greta Miño; Marco T Luque; Adrián Collia; Enrique Faugier-Fuentes; Heloisa Helena de Sousa Marques; Martha I Álvarez-Olmos; Kathia Luciani; María Catalina Pírez; Fernanda Cofré; German Camacho-Moreno; Virgen Gomez; Marco Antonio Yamazaki-Nakashimada; Diana López-Gallegos; Angélica Calvache-Burbano; María Luisa Ávila-Agüero; Giannina Izquierdo; Kattia Camacho-Badilla; Alejandra Soriano-Fallas; Kathia Valverde; Raymundo Rodriguez-Herrera; Enrique Chacon-Cruz; Antonio Fernández; Lucila Martínez-Medina; Luisa Berenise Gámez-González
Collaboration
Dive into the Luisa Berenise Gámez-González's collaboration.
Marco Antonio Yamazaki-Nakashimada
National Autonomous University of Mexico
View shared research outputs